| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tiziana Bisogno, Maria Grazia Cascio, Bijali Saha, Anu Mahadevan, Paolo Urbani, Alberto Minassi, Giovanni Appendino, Carmela Saturnino, Billy Martin, Raj Razdan, Vincenzo Di Marz. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochimica et biophysica acta. vol 1761. issue 2. 2006-05-31. PMID:16466961. |
apart from being almost inactive on magl, these two compounds showed high selectivity over rat liver triacylglycerol lipase, rat n-acylphosphatidyl-ethanolamine-selective phospholipase d (involved in anandamide biosynthesis), rat fatty acid amide hydrolase and human recombinant cannabinoid cb1 and cb2 receptors. |
2006-05-31 |
2023-08-12 |
human |
| John M McPartland, Isabel Matias, Vincenzo Di Marzo, Michelle Glas. Evolutionary origins of the endocannabinoid system. Gene. vol 370. 2006-05-26. PMID:16434153. |
within this limited number of twelve organisms, the endocannabinoid genes exhibited heterogeneous evolutionary trajectories, with functional orthologs limited to mammals (trpv1 and gpr55), or vertebrates (cb2 and daglbeta), or chordates (magl and cox2), or animals (daglalpha and cb1-like receptors), or opisthokonta (animals and fungi, nape-pld), or eukaryotes (faah). |
2006-05-26 |
2023-08-12 |
mouse |
| Ganesh A Thakur, Spyros P Nikas, Richard I Duclos, Alexandros Makriyanni. Methods for the synthesis of cannabinergic ligands. Methods in molecular medicine. vol 123. 2006-05-26. PMID:16506405. |
during the last decade, numerous cannabinergic ligands with high affinity and selectivity profiles for cannabinoid receptors (cb1 and cb2) emerged from rigorously pursued structure-activity relationship studies. |
2006-05-26 |
2023-08-12 |
Not clear |
| Nissar A Darman. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. Methods in molecular medicine. vol 123. 2006-05-26. PMID:16506408. |
both delta9-tetrahydrocannibinol (delta9-thc) and well-studied representatives of other classes of exogenous cannabinoid cb1/cb2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid cb1 receptors since the cb1 (sr141716a)- and not the cb2 (sr144528)-receptor antagonist reverses these effects in a dose-dependent manner. |
2006-05-26 |
2023-08-12 |
human |
| Emmanuel S Onaivi, Hiroki Ishiguro, Patel Sejal, Paul A Meozzi, Lester Myers, Patricia Tagliaferro, Bruce Hope, Claire M Leonard, George R Uhl, Alicia Brusco, Eileen Gardne. Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression. Methods in molecular medicine. vol 123. 2006-05-26. PMID:16506415. |
it is unknown whether cb2 cannabinoid receptors are expressed in the brain and whether they are involved in depression and substance abuse. |
2006-05-26 |
2023-08-12 |
mouse |
| John W Huffman, Simon M Bushell, Sudhir N Joshi, Jenny L Wiley, Billy R Marti. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorganic & medicinal chemistry. vol 14. issue 1. 2006-05-04. PMID:16165365. |
two new series of cannabinoids were prepared and their affinities for the cb1 and cb2 receptors were determined. |
2006-05-04 |
2023-08-12 |
Not clear |
| D Lamontagne, P Lépicier, C Lagneux, J F Bouchar. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Archives des maladies du coeur et des vaisseaux. vol 99. issue 3. 2006-05-04. PMID:16618028. |
hence, arachidonoylethanolamide (anandamide) and sn-2 arachidonoylglycerol, the first two endocannabinoids identified, are formed from plasma membrane phospholipids and act as cb1 and/or cb2 agonists. |
2006-05-04 |
2023-08-12 |
mouse |
| John C Ashton, Deborah Friberg, Cynthia L Darlington, Paul F Smit. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neuroscience letters. vol 396. issue 2. 2006-04-25. PMID:16356641. |
expression of the cannabinoid cb2 receptor in the rat cerebellum: an immunohistochemical study. |
2006-04-25 |
2023-08-12 |
rat |
| John C Ashton, Deborah Friberg, Cynthia L Darlington, Paul F Smit. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neuroscience letters. vol 396. issue 2. 2006-04-25. PMID:16356641. |
reports of cannabinoid cb2 receptor protein in the brain have been ambiguous. |
2006-04-25 |
2023-08-12 |
rat |
| Grzegorz Kwolek, Agnieszka Zakrzeska, Hanna Kozłowska, Barbara Malinowsk. [Influence of anandamide, the endogenous agonist of cannabinoid receptors on the circulatory system]. Postepy higieny i medycyny doswiadczalnej (Online). vol 59. 2006-04-24. PMID:15928605. |
these agents are now known to act through the cannabinoid cb1 and cb2 receptors. |
2006-04-24 |
2023-08-12 |
human |
| A C Howlet. Cannabinoid receptor signaling. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596771. |
evidence exists for cannabinoid receptor-mediated ca2+ fluxes and stimulation of phospholipases a and c. stimulation of cb1 and cb2 cannabinoid receptors leads to phosphorylation and activation of p42/p44 mitogen-activated protein kinase (mapk), p38 mapk and jun n-terminal kinase (jnk) as signaling pathways to regulate nuclear transcription factors. |
2006-04-19 |
2023-08-12 |
Not clear |
| M E Aboo. Molecular biology of cannabinoid receptors. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596772. |
the cb1 and cb2 cannabinoid receptors are members of the g protein-coupled receptor family. |
2006-04-19 |
2023-08-12 |
Not clear |
| M E Aboo. Molecular biology of cannabinoid receptors. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596772. |
the cb1 and cb2 receptors recognize endogenous and exogenous cannabinoid compounds, which fall into five structurally diverse classes. |
2006-04-19 |
2023-08-12 |
Not clear |
| G A Thakur, S P Nikas, C Li, A Makriyanni. Structural requirements for cannabinoid receptor probes. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596776. |
the discovery and cloning of cb1 and cb2, the two known g(i/o) protein-coupled cannabinoid receptors, as well as the isolation and characterization of two families of endogenous cannabinergic ligands represented by arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-ag), have opened new horizons in this newly discovered field of biology. |
2006-04-19 |
2023-08-12 |
Not clear |
| P H Reggi. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596777. |
the cannabinoid cb1 and cb2 receptors belong to the class a, rhodopsin-like family of gpcrs. |
2006-04-19 |
2023-08-12 |
Not clear |
| C W Vaughan, M J Christi. Retrograde signalling by endocannabinoids. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596781. |
the cannabinoid neurotransmitter system comprises cannabinoid g protein-coupled membrane receptors (cb1 and cb2), endogenous cannabinoids (endocannabinoids), as well as mechanisms for their synthesis, membrane transport and metabolism. |
2006-04-19 |
2023-08-12 |
Not clear |
| G A Cabral, A Staa. Effects on the immune system. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596782. |
first, cannabinoids may signal through the cannabinoid receptors cb1 and cb2. |
2006-04-19 |
2023-08-12 |
Not clear |
| J Fernández-Ruiz, S Gonzále. Cannabinoid control of motor function at the basal ganglia. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596785. |
this finding is supported by three-fold evidence: (1) the abundance of the cannabinoid cb1 receptor subtype, but also of cb2 and vanilloid vr1 receptors, as well as of endocannabinoids in the basal ganglia and the cerebellum, the areas that control movement; (2) the demonstration of a powerful action, mostly of an inhibitory nature, of plant-derived, synthetic, and endogenous cannabinoids on motor activity, exerted by modulating the activity of various classic neurotransmitters; and (3) the occurrence of marked changes in endocannabinoid transmission in the basal ganglia of humans affected by several motor disorders, an event corroborated in animal models of these neurological diseases. |
2006-04-19 |
2023-08-12 |
Not clear |
| J M Walker, A G Hohman. Cannabinoid mechanisms of pain suppression. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596786. |
these studies provide insight into the functional roles of cannabinoid cb1 (cb1r) and cb2 (cb2r) receptor subtypes in cannabinoid antinociceptive mechanisms, as revealed in animal models of acute and persistent pain. |
2006-04-19 |
2023-08-12 |
human |
| Daniele Piomell. The endocannabinoid system: a drug discovery perspective. Current opinion in investigational drugs (London, England : 2000). vol 6. issue 7. 2006-04-18. PMID:16044662. |
they are produced by cells in the brain and other tissues and combine with two subtypes of g protein-coupled cannabinoid receptors, cb1 and cb2. |
2006-04-18 |
2023-08-12 |
Not clear |